MarketCapExport financials
Akers Biosciences, Inc. (AKER)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
TelegramAkers Biosciences, Inc. Financial Statements 2020-2011 | AKER
Annual Financial Statements Akers Biosciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
809 K | 888 K | 6.36 M | 1.2 M | 3.26 M | 3.08 M | 8 M | 4.14 M | - | - |
Shares |
306 K | 306 K | 229 K | 24.7 K | 14.1 K | 13.4 K | 12.4 K | 4.16 K | - | - |
Net Income |
-17.6 M | -3.89 M | -10.8 M | -5.81 M | -3.3 M | -9.31 M | -3.13 M | -1.53 M | -2.45 M | -3.58 M |
Revenue |
- | 1.58 M | 1.67 M | 3.93 M | 2.96 M | 2.12 M | 4.43 M | 3.58 M | 1.52 M | 1.79 M |
EBITDA |
-12.3 M | -3.76 M | -8.38 M | -4.88 M | -4.46 M | -6.82 M | -2.95 M | -1.55 M | -2.19 M | -3.33 M |
Operating Expenses |
7.99 M | 4.28 M | 8.68 M | 7.56 M | 6.51 M | 8.22 M | 6.46 M | 3.47 M | 3.17 M | 4.74 M |
General and Administrative Expenses |
- | 3.73 M | 5.67 M | 4.08 M | 3.01 M | 4.03 M | 3.98 M | 1.52 M | 1.49 M | 3.28 M |
Annual performance
Select metrics to display
All numbers in USD currency
Main types of financial statements Akers Biosciences, Inc. AKERFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Akers Biosciences, Inc. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Alcon
ALC
|
$ 72.29 | -2.39 % | $ 35.7 B |  Schweiz |
 |
electroCore
ECOR
|
$ 7.74 | 0.26 % | $ 65.7 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 449.23 | -0.18 % | $ 160 B | USA |
 |
The Cooper Companies
COO
|
$ 62.93 | -1.01 % | $ 12.5 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.55 | 0.04 % | $ 16.5 M | USA |
 |
STERIS plc
STE
|
$ 256.26 | -0.35 % | $ 25.2 B | USA |
 |
Utah Medical Products
UTMD
|
$ 73.41 | 0.75 % | $ 238 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.77 | 0.72 % | $ 1.95 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 15.0 | -1.83 % | $ 310 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 88.65 | 3.01 % | $ 2.84 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.55 | 6.61 % | $ 261 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 26.41 | 10.64 % | $ 1.31 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 155.91 | 0.55 % | $ 6.96 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 213.53 | 0.4 % | $ 61.4 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 413.04 | 0.12 % | $ 29.9 B | USA |
 |
Baxter International
BAX
|
$ 26.37 | -0.15 % | $ 13.5 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.73 | 17.88 % | $ 172 M | USA |
 |
AtriCure
ATRC
|
$ 57.54 | 2.28 % | $ 2.75 B | USA |
 |
AngioDynamics
ANGO
|
$ 12.41 | 2.82 % | $ 515 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 246.34 | 4.15 % | $ 14.1 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 9.81 | 5.94 % | $ 435 M | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Microbot Medical
MBOT
|
$ 1.11 | 5.71 % | $ 50.8 M |  Israel |
 |
Haemonetics Corporation
HAE
|
$ 120.49 | -1.58 % | $ 5.68 B | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
ICU Medical
ICUI
|
$ 178.32 | -2.15 % | $ 4.39 B | USA |
 |
ResMed
RMD
|
$ 238.38 | 1.81 % | $ 34.7 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.31 | 1.7 % | $ 25.4 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 88.19 | 0.43 % | $ 5.22 B | USA |
 |
Nephros
NEPH
|
$ 3.09 | -2.06 % | $ 32.8 M | USA |
 |
Pro-Dex
PDEX
|
$ 71.2 | 1.92 % | $ 230 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.33 | -1.99 % | $ 4.26 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 79.26 | 0.3 % | $ 1.79 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 56.65 | 2.77 % | $ 3.82 B | USA |
 |
Repligen Corporation
RGEN
|
$ 172.96 | -0.59 % | $ 9.73 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Stereotaxis
STXS
|
$ 0.9 | -12.63 % | $ 81.9 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |